Pipeline Update: New Antifungals Sprout In Warmer Regulatory Climate
Candidates from Cidara, Scynexis, Viamet and more featured in a symposium at the ICAAC/ICC meeting in September.
You may also be interested in...
Better Incentives Needed For Worsening Fungal Infection Threat
The increasing threat of treatment-resistant Candida auris fungal infections suggests the need for greater development incentives, CEOs of three antifungal drug developers told the recent BIO annual meeting.
Antibiotics: Officially Encouraged, Increasingly Precise, Still Risky
Anti-infective start-ups getting funded these days say they can boost the odds of clinical success, and reduce the cost of achieving it. Profiles of EnBiotix, Nosopharm, and Spero Therapeutics.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.